Crystalline form of (2s)-(-)-N-(6-chloro-2,3-dihydro-benzo[1 ,4]dioxin-2-ylmethyl)-sulfamide

Details for Australian Patent Application No. 2009271362 (hide)

Owner Janssen Pharmaceutica NV

Inventors Wu, Wenju; Mehrman, Steven J.

Agent Shelston IP

Pub. Number AU-A-2009271362

PCT Pub. Number WO2010/008776

Priority 61/074,783 23.06.08 US

Filing date 19 June 2009

Wipo publication date 21 January 2010

International Classifications

C07D 319/16 (2006.01) Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms

A61K 31/357 (2006.01) - having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel

A61P 3/04 (2006.01) Drugs for disorders of the metabolism

A61P 25/00 (2006.01) Drugs for disorders of the nervous system

A61P 25/24 (2006.01) Drugs for disorders of the nervous system

A61P 25/30 (2006.01) Drugs for disorders of the nervous system

Event Publications

20 January 2011 PCT application entered the National Phase

  PCT publication WO2010/008776 Priority application(s): WO2010/008776

19 May 2011 Amendment Made

  The nature of the amendment is as shown in the statement(s) filed 04 Jan 2011 and 29 Apr 2011

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2009271367-Method for packaging semiconductors at a wafer level

2009271352-Authentication segmentation